Answer
The most common serious adverse reactions to imlifidase in clinical studies were pneumonia (5.6%) and sepsis (3.7%).
Sources for this answer
- Idefirix 11 mg powder for concentrate for solution for infusionHansa Biopharma AB · emc · SmPC §4.8 Undesirable effects · Version 7Document updated
Sources checked